Portola Pharmaceuticals Inc (PTLA) Given Average Rating of “Buy” by Analysts

Portola Pharmaceuticals Inc (NASDAQ:PTLA) has been assigned an average recommendation of “Buy” from the twelve brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $70.74.

PTLA has been the topic of several recent research reports. Morgan Stanley reissued an “overweight” rating and issued a $81.00 price target (up previously from $75.00) on shares of Portola Pharmaceuticals in a report on Friday, October 6th. Oppenheimer set a $80.00 price target on Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, October 6th. Goldman Sachs Group initiated coverage on Portola Pharmaceuticals in a report on Friday, December 1st. They issued a “buy” rating and a $75.00 price target on the stock. BidaskClub cut Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 7th. Finally, Citigroup restated a “buy” rating and issued a $74.00 target price on shares of Portola Pharmaceuticals in a research report on Thursday, December 28th.

In related news, Director Henry Ward Wolff sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $47.00, for a total value of $564,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.50% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Amalgamated Bank increased its position in Portola Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,376 shares of the biopharmaceutical company’s stock valued at $358,000 after acquiring an additional 328 shares during the period. Principal Financial Group Inc. increased its position in Portola Pharmaceuticals by 0.6% in the 2nd quarter. Principal Financial Group Inc. now owns 62,693 shares of the biopharmaceutical company’s stock valued at $3,521,000 after acquiring an additional 371 shares during the period. Legal & General Group Plc increased its position in Portola Pharmaceuticals by 2.8% in the 2nd quarter. Legal & General Group Plc now owns 18,870 shares of the biopharmaceutical company’s stock valued at $1,062,000 after acquiring an additional 506 shares during the period. Quantbot Technologies LP increased its position in Portola Pharmaceuticals by 25.2% in the 3rd quarter. Quantbot Technologies LP now owns 5,853 shares of the biopharmaceutical company’s stock valued at $316,000 after acquiring an additional 1,177 shares during the period. Finally, California Public Employees Retirement System increased its position in shares of Portola Pharmaceuticals by 3.8% during the 3rd quarter. California Public Employees Retirement System now owns 40,500 shares of the biopharmaceutical company’s stock valued at $2,188,000 after purchasing an additional 1,500 shares during the period. Hedge funds and other institutional investors own 87.27% of the company’s stock.

Shares of Portola Pharmaceuticals (PTLA) traded up $2.10 during midday trading on Friday, hitting $54.23. The company had a trading volume of 951,403 shares, compared to its average volume of 1,130,000. The company has a market cap of $3,680.00, a P/E ratio of -12.55 and a beta of 1.21. Portola Pharmaceuticals has a 1-year low of $24.70 and a 1-year high of $67.10. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.08. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $4.71 million. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The business’s revenue was down 58.9% on a year-over-year basis. During the same quarter last year, the business posted ($1.64) EPS. equities research analysts forecast that Portola Pharmaceuticals will post -4.94 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://ledgergazette.com/2018/02/11/portola-pharmaceuticals-inc-ptla-given-average-rating-of-buy-by-analysts.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply